TY - JOUR
T1 - Evaluation of antigen-specific immunoglobulin g responses in pulmonary tuberculosis patients and contacts
AU - Hur, Yun Gyoung
AU - Kim, Ahreum
AU - Kang, Young Ae
AU - Kim, An Sik
AU - Kim, Dae Yeon
AU - Kim, Yeun
AU - Kim, Youngmi
AU - Lee, Hyeyoung
AU - Cho, Sang Nae
N1 - Publisher Copyright:
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - This study aimed to evaluate the serodiagnostic potential of immunoglobulin G (IgG) responses to Mycobacterium tuberculosis antigens in pulmonary tuberculosis (TB) patients, recent TB contacts with latent TB infection (LTBI), and healthy subjects. Infections were assessed using tuberculin skin tests, QuantiFERON-TB Gold In-Tube tests, drug susceptibility testing, and molecular genotyping of clinical isolates. Serum IgG responses to selective M. tuberculosis antigens, including the 38-kDa and 16-kDa antigens, lipoarabinomannan (LAM), and recombinant early secreted antigen target 6 kDa (ESAT-6) and culture filtrate protein 10 kDa (CFP-10), were determined. We found that the serum IgG responses to all antigens might differentiate between active TB and LTBI, with LAM having the highest diagnostic value (area under the curve [AUC] of 0.7756, P<0.001). Recurrent TB cases showed significantly higher IgG responses to 38 kDa, CFP-10 (P<0.01), and LAM (P<0.05) than new cases, and male patients had higher levels of antigen-specific IgG than females (P<0.05). Conversely, drug resistance and patient body mass index did not affect IgG responses (P>0.05). LAM-specific IgG responses differentiated between acid-fast bacillus (AFB) smearpositive and -negative patients (P<0.01), whereas antigen-specific IgG responses did not vary with the M. tuberculosis genotype (P>0.05). Significantly higher IgG responses to 38 kDa and 16 kDa were observed in AFB smear-negative patients than in controls. These results suggest that assessment of serum IgG responses to selective purified M. tuberculosis antigens may help improve the diagnosis of active TB, particularly for sputum smear-negative patients or recurrent cases, and these may also help to differentiate between active TB and LTBI.
AB - This study aimed to evaluate the serodiagnostic potential of immunoglobulin G (IgG) responses to Mycobacterium tuberculosis antigens in pulmonary tuberculosis (TB) patients, recent TB contacts with latent TB infection (LTBI), and healthy subjects. Infections were assessed using tuberculin skin tests, QuantiFERON-TB Gold In-Tube tests, drug susceptibility testing, and molecular genotyping of clinical isolates. Serum IgG responses to selective M. tuberculosis antigens, including the 38-kDa and 16-kDa antigens, lipoarabinomannan (LAM), and recombinant early secreted antigen target 6 kDa (ESAT-6) and culture filtrate protein 10 kDa (CFP-10), were determined. We found that the serum IgG responses to all antigens might differentiate between active TB and LTBI, with LAM having the highest diagnostic value (area under the curve [AUC] of 0.7756, P<0.001). Recurrent TB cases showed significantly higher IgG responses to 38 kDa, CFP-10 (P<0.01), and LAM (P<0.05) than new cases, and male patients had higher levels of antigen-specific IgG than females (P<0.05). Conversely, drug resistance and patient body mass index did not affect IgG responses (P>0.05). LAM-specific IgG responses differentiated between acid-fast bacillus (AFB) smearpositive and -negative patients (P<0.01), whereas antigen-specific IgG responses did not vary with the M. tuberculosis genotype (P>0.05). Significantly higher IgG responses to 38 kDa and 16 kDa were observed in AFB smear-negative patients than in controls. These results suggest that assessment of serum IgG responses to selective purified M. tuberculosis antigens may help improve the diagnosis of active TB, particularly for sputum smear-negative patients or recurrent cases, and these may also help to differentiate between active TB and LTBI.
UR - http://www.scopus.com/inward/record.url?scp=84923344007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923344007&partnerID=8YFLogxK
U2 - 10.1128/JCM.03050-14
DO - 10.1128/JCM.03050-14
M3 - Article
C2 - 25588651
AN - SCOPUS:84923344007
SN - 0095-1137
VL - 53
SP - 904
EP - 909
JO - Journal of Clinical Microbiology
JF - Journal of Clinical Microbiology
IS - 3
ER -